Kinase News and Research

RSS

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.

16 Sep 2011

Researchers identify promising new therapies for ependymoma

Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system that combines the latest drug screening technology with the first accurate animal model of the tumor.

16 Sep 2011

Differences in lifestyle, tumor genetics linked to head and neck cancer in African Americans

Why are African Americans more likely than Caucasians to be not only diagnosed with head and neck cancer, but also die from the disease? While the answer isn't a simple one, differences in lifestyle, access to care and tumor genetics may, in part, be to blame, according to a new study from Henry Ford Hospital.

15 Sep 2011

Celecoxib inhibits GSK3 enzyme in lung cancer cells

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Curcumin suppresses cell signaling pathway that drives growth of head and neck cancer

Curcumin, the main component in the spice turmeric, suppresses a cell signaling pathway that drives the growth of head and neck cancer, according to a pilot study using human saliva by researchers at UCLA's Jonsson Comprehensive Cancer Center.

14 Sep 2011

Hawthorn, CoPlex Therapeutics sign licensing deal to develop and commercialize hawAD14 for Alzheimer's

Hawthorn Pharmaceuticals, Inc. announced today an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

13 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

PKC epsilon enzyme might be target for treatment of nicotine addiction, alcohol abuse

An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, according to a study by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco.

9 Sep 2011

ATA announces five recipients of 2011 thyroid cancer research grants

The American Thyroid Association (ATA) announced the five recipients of its 2011 research grants, each of whom will receive up to $25,000 annually for up to two years. Three of the five recipients were awarded special ATA ThyCa grants for research projects that focus on thyroid cancer. These grants are funded by ThyCa: Thyroid Cancer Survivors, Inc.

8 Sep 2011

Inhibition of Sab protein protects liver from acetaminophen toxicity

New research from the Keck School of Medicine of the University of Southern California (USC) may help prevent damage to the liver caused by drugs like acetaminophen and other stressors.

8 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

McMaster team demonstrates essential role of AMPK enzyme in exercise

You may think your lack of resolve to get off the couch to exercise is because you're lazy, but McMaster University researchers have discovered it may be you are missing key genes.

6 Sep 2011

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Study describes new class of anti-diabetic compound that targets unique molecular switch

In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.

5 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

University of Florida researchers have modified a toxic chemical produced by tiny marine microbes and successfully deployed it against laboratory models of colon cancer.

2 Sep 2011

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.

2 Sep 2011

Kinase News and Research

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Researchers identify promising new therapies for ependymoma

Differences in lifestyle, tumor genetics linked to head and neck cancer in African Americans

Celecoxib inhibits GSK3 enzyme in lung cancer cells

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Curcumin suppresses cell signaling pathway that drives growth of head and neck cancer

Hawthorn, CoPlex Therapeutics sign licensing deal to develop and commercialize hawAD14 for Alzheimer's

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

PKC epsilon enzyme might be target for treatment of nicotine addiction, alcohol abuse

ATA announces five recipients of 2011 thyroid cancer research grants

Inhibition of Sab protein protects liver from acetaminophen toxicity

Amakem receives €18m in Series A round of funding

McMaster team demonstrates essential role of AMPK enzyme in exercise

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

Study describes new class of anti-diabetic compound that targets unique molecular switch

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

Researchers modify toxic chemical of marine cycyanobacteria to treat colon cancer

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News